OMRON Ventures Co., Ltd. (CEO: Tomoko Inoue) is pleased to announce that it has made an investment in Avails Medical, Inc. (headquartered in Menlo Park, USA), which develops devices that accelerate antibiotic susceptibility testing (AST) for infectious diseases.

Antibiotic resistance is an increasingly serious problem all over the world. By investing in technologies that can dramatically reduce the time required to perform AST and choose the most appropriate antibiotic for a patient, OMRON Ventures aims to contribute to the fight to rid the world of drug-resistant pathogens.